GT Biopharma Inc (GTBP) Stock Price, Quote & News

Company Profile

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumo...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 919 4040

Website: www.gtbiopharma.com

Address:

315 Montgomery Street, 10th Floor, San Francisco, United States

calderinho May. 27 at 9:42 AM

$GTBP

0 · Reply

stocks_2watch May. 26 at 6:17 AM

Interview - GT BioPharma ($GTBP): TriKE®️ Platform, Cancer Trials, and Clinical Milestones, latest: https://www.youtube.com/watch?v=Wktvzn0MzQ4

0 · Reply

BigD_Love May. 22 at 3:46 PM

$GTBP Really nice move here today… LFG! 👊🏻

1 · Reply

DARKP00L May. 22 at 12:18 PM

$GTBP 08:11 on May. 22 2026 Nasdaq Grants GT Biopharma Additional 180 Days To Regain Compliance #tradeideas

0 · Reply

focafoca99 May. 22 at 12:17 PM

$GTBP notified Nasdaq that it received an additional 180‑day compliance period to regain $1.00 minimum bid price.

0 · Reply

1flaguy May. 22 at 12:10 PM

$GTBP They got the approval for another 180 days for NASDAQ

0 · Reply

Waterwing May. 21 at 9:28 PM

$GTBP

0 · Reply

Noetic83 May. 20 at 1:04 PM

$GTBP in @ .4399

0 · Reply

Outcomes May. 19 at 11:51 PM

$GTBP $IBRX $CRDL ....saw a TV ad for GTBP and decided to take a look 🤔🤣

0 · Reply

The_Capt May. 19 at 3:23 PM

$GTBP All Aboard 🚀🌜

0 · Reply

GT Biopharma Reports First Quarter 2026 Financial Results

May 15, 2026, 7:00 AM EDT - 12 days ago

GT Biopharma Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 12 days ago

GT Biopharma Earnings release: Q1 2026

2026-05-14T14:05:26.000Z - 13 days ago

GT Biopharma doses first patient in GTB-5550 trial

May 14, 2026, 8:30 AM EDT - 13 days ago

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

2026-04-30T21:13:17.000Z - 26 days ago

GT Biopharma files to sell 9.72M shares of common stock for holders

Apr 30, 2026, 8:00 AM EDT - 27 days ago

GT Biopharma Registration statement: Registration filing

Apr 16, 2026, 2:00 PM EDT - 5 weeks ago

GT Biopharma Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

Mar 9, 2026, 7:00 AM EDT - 2 months ago

GT Biopharma Slides: Corporate presentation

2026-03-03T13:31:45.000Z - 3 months ago

GT Biopharma price target lowered to $3 from $8 at Roth Capital

2026-03-02T21:36:20.000Z - 3 months ago

GT Biopharma price target lowered to $3 from $8 at Roth Capital

2026-03-02T12:12:33.000Z - 3 months ago

GT Biopharma expects cash to fund operations through Q4 2026

Mar 2, 2026, 7:00 AM EST - 3 months ago

GT Biopharma Reports Full Year 2025 Financial Results

Mar 2, 2026, 7:00 AM EST - 3 months ago

GT Biopharma Earnings release: Q4 2025

Mar 2, 2026, 7:00 AM EST - 3 months ago

GT Biopharma Annual report: Q4 2025

Feb 17, 2026, 7:30 AM EST - 3 months ago

GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference

2026-02-03T13:35:12.000Z - 4 months ago

GT Biopharma announces FDA clearance of IND application for GTB-5550

Feb 3, 2026, 8:30 AM EST - 4 months ago

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3

Jan 21, 2026, 7:00 AM EST - 4 months ago

GT Biopharma Registration statement: Registration Filing

2026-01-15T13:36:22.000Z - 4 months ago

GT Biopharma submits IND application to U.S. FDA for GTB-5550 TriKE

Jan 15, 2026, 8:30 AM EST - 4 months ago

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

Dec 19, 2025, 7:44 AM EST - 5 months ago

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030

Nov 19, 2025, 8:00 AM EST - 6 months ago

GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials

2025-11-17T13:10:48.000Z - 6 months ago

GT Biopharma price target lowered to $8 from $11 at Roth Capital

2025-11-14T14:05:16.000Z - 6 months ago

GT Biopharma reports Q3 net loss $3.1M vs $3.4M last year

Nov 14, 2025, 9:00 AM EST - 6 months ago

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 14, 2025, 9:00 AM EST - 6 months ago

GT Biopharma Quarterly report: Q3 2025

Nov 14, 2025, 9:00 AM EST - 6 months ago

GT Biopharma Earnings release: Q3 2025

2025-10-24T20:20:16.000Z - 7 months ago

GT Biopharma files to sell 14.59M shares of common stock for holders

Oct 24, 2025, 8:00 AM EDT - 7 months ago

GT Biopharma Registration statement: Registration Filing

2025-10-08T13:10:29.000Z - 8 months ago

GT Biopharma provides enrollment update on GTB-3650 Phase 1 Trial

Sep 5, 2025, 7:00 AM EDT - 9 months ago

GT Biopharma Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 4:05 PM EDT - 10 months ago

GT Biopharma Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 7:00 AM EDT - 10 months ago

GT Biopharma Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 10 months ago

GT Biopharma Quarterly report: Q2 2025

2025-08-11T11:21:57.000Z - 10 months ago

GT Biopharma advances into cohort 3 of GTB-3650 Phase 1 trial

Aug 11, 2025, 7:00 AM EDT - 10 months ago

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

Jun 27, 2025, 8:00 AM EDT - 11 months ago

GT Biopharma Registration statement: Registration Filing

2025-06-13T13:10:35.000Z - 1 year ago

GT Biopharma appoints Mun-Gavin to board of directors

Jun 13, 2025, 9:00 AM EDT - 1 year ago

GT Biopharma Appoints New Member to its Board of Directors

2025-06-11T21:40:29.000Z - 1 year ago

GT Biopharma files to sell 120.55M shares of common stock for holders

Jun 11, 2025, 8:00 AM EDT - 1 year ago

GT Biopharma Registration statement: Registration Filing

Jun 11, 2025, 8:00 AM EDT - 1 year ago

GT Biopharma Proxy statement: Proxy Filing

Jun 11, 2025, 8:00 AM EDT - 1 year ago

GT Biopharma Proxy statement: Proxy Filing

May 30, 2025, 8:00 AM EDT - 1 year ago

GT Biopharma Proxy statement: Proxy Filing

2025-05-19T13:10:50.000Z - 1 year ago

GT Biopharma advances GTB-3650 Phase 1 trial to Cohort 2

May 19, 2025, 9:00 AM EDT - 1 year ago

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

May 15, 2025, 4:00 PM EDT - 1 year ago

GT Biopharma Quarterly report: Q1 2025

2025-05-15T13:16:23.000Z - 1 year ago

GT Biopharma appoints Andrew Ritter to board of directors

May 15, 2025, 6:00 AM EDT - 1 year ago

GT Biopharma Slides: Corporate Presentation

2025-05-14T11:32:30.000Z - 1 year ago

GT Biopharma appoints Kramer to board of directors

2025-03-06T22:25:27.000Z - 1 year ago

GT Biopharma files to sell 625,283 shares of common stock for holders

Mar 6, 2025, 7:00 AM EST - 1 year ago

GT Biopharma Registration statement: Registration Filing

Feb 25, 2025, 2:00 PM EST - 1 year ago

GT Biopharma Announces Exercise of Warrants

2025-02-25T17:40:40.000Z - 1 year ago

GT Biopharma could report Phase 1 trial data later this year, says Roth MKM

2025-02-25T12:30:51.000Z - 1 year ago

GT Biopharma announces request for withdrawal of Form S-1 registration statement

Feb 21, 2025, 3:00 PM EST - 1 year ago

GT Biopharma Annual report: Q4 2024

Feb 7, 2025, 7:00 AM EST - 1 year ago

GT Biopharma Registration statement: Registration Filing

Jan 27, 2025, 7:00 AM EST - 1 year ago

GT Biopharma Registration statement: Registration Filing

Dec 23, 2024, 7:00 AM EST - 1 year ago

GT Biopharma Registration statement: Registration Filing

Nov 19, 2024, 7:00 AM EST - 1 year ago

GT Biopharma Slides: Corporate Presentation

Nov 14, 2024, 4:00 PM EST - 1 year ago

GT Biopharma Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 7:00 AM EST - 1 year ago

GT Biopharma Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

GT Biopharma Earnings release: Q3 2024

Sep 26, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 24, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

Aug 14, 2024, 7:00 AM EDT - 1 year ago

GT Biopharma Quarterly report: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 1 year ago

GT Biopharma Earnings release: Q2 2024

Jun 27, 2024, 9:15 AM EDT - 2 years ago

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

Jun 27, 2024, 8:00 AM EDT - 2 years ago

GT Biopharma Registration statement: Registration Filing

Jun 20, 2024, 8:00 AM EDT - 2 years ago

GT Biopharma Registration statement: Registration Filing

Jun 17, 2024, 8:00 AM EDT - 2 years ago

GT Biopharma Proxy statement: Proxy Filing

May 21, 2024, 9:15 AM EDT - 2 years ago

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 20, 2024, 10:43 AM EDT - 2 years ago

What made GT Biopharma stock more than double on Monday?

May 15, 2024, 5:00 PM EDT - 2 years ago

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 15, 2024, 7:00 AM EDT - 2 years ago

GT Biopharma Quarterly report: Q1 2024

May 15, 2024, 7:00 AM EDT - 2 years ago

GT Biopharma Earnings release: Q1 2024

Apr 29, 2024, 8:00 AM EDT - 2 years ago

GT Biopharma Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

GT Biopharma Proxy statement: Proxy Filing

Mar 26, 2024, 5:00 PM EDT - 2 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Mar 26, 2024, 8:00 AM EDT - 2 years ago

GT Biopharma Annual report: Q4 2023

Mar 26, 2024, 8:00 AM EDT - 2 years ago

GT Biopharma Earnings release: Q4 2023

Feb 1, 2024, 11:00 AM EST - 2 years ago

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

Dec 6, 2023, 9:30 AM EST - 2 years ago

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

Dec 4, 2023, 9:30 AM EST - 2 years ago

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

Nov 6, 2023, 9:30 AM EST - 2 years ago

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Nov 6, 2023, 7:00 AM EST - 2 years ago

GT Biopharma Proxy statement: Proxy Filing

Nov 6, 2023, 7:00 AM EST - 2 years ago

GT Biopharma Proxy statement: Proxy Filing

Nov 6, 2023, 7:00 AM EST - 2 years ago

GT Biopharma Proxy statement: Proxy Filing

Nov 1, 2023, 9:00 AM EDT - 2 years ago

GT Biopharma Reports Third Quarter 2023 Financial Results

Nov 1, 2023, 8:00 AM EDT - 2 years ago

GT Biopharma Quarterly report: Q3 2023

Nov 1, 2023, 8:00 AM EDT - 2 years ago

GT Biopharma Earnings release: Q3 2023

Oct 27, 2023, 8:00 AM EDT - 2 years ago

GT Biopharma Proxy statement: Proxy Filing

Aug 7, 2023, 9:00 AM EDT - 3 years ago

GT Biopharma Reports Second Quarter 2023 Financial Results

Aug 7, 2023, 7:00 AM EDT - 3 years ago

GT Biopharma Quarterly report: Q2 2023

Aug 7, 2023, 7:00 AM EDT - 3 years ago

GT Biopharma Earnings release: Q2 2023

Aug 3, 2023, 1:25 PM EDT - 3 years ago

GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

May 15, 2023, 5:00 PM EDT - 3 years ago

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 15, 2023, 7:00 AM EDT - 3 years ago

GT Biopharma Quarterly report: Q1 2023

May 15, 2023, 7:00 AM EDT - 3 years ago

GT Biopharma Earnings release: Q1 2023

May 5, 2023, 8:00 AM EDT - 3 years ago

GT Biopharma Proxy statement: Proxy Filing

May 5, 2023, 8:00 AM EDT - 3 years ago

GT Biopharma Proxy statement: Proxy Filing

May 4, 2023, 9:05 AM EDT - 3 years ago

GT Biopharma Names Charles J. Casamento to the Board of Directors

May 1, 2023, 8:00 AM EDT - 3 years ago

GT Biopharma Proxy statement: Proxy Filing

Mar 30, 2023, 5:00 PM EDT - 3 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

Mar 30, 2023, 7:00 AM EDT - 3 years ago

GT Biopharma Annual report: Q4 2022

Mar 30, 2023, 7:00 AM EDT - 3 years ago

GT Biopharma Earnings release: Q4 2022

Feb 24, 2023, 9:00 AM EST - 3 years ago

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

Feb 2, 2023, 9:46 AM EST - 3 years ago

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

Dec 30, 2022, 8:00 AM EST - 3 years ago

GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market

Dec 14, 2022, 7:30 AM EST - 3 years ago

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

Dec 12, 2022, 7:30 AM EST - 3 years ago

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

Nov 10, 2022, 3:15 PM EST - 3 years ago

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Nov 3, 2022, 9:00 AM EDT - 3 years ago

GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting

Oct 31, 2022, 5:15 PM EDT - 3 years ago

GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update

Oct 31, 2022, 8:00 AM EDT - 3 years ago

GT Biopharma Quarterly report: Q3 2022

Oct 31, 2022, 8:00 AM EDT - 3 years ago

GT Biopharma Earnings release: Q3 2022

Oct 25, 2022, 2:44 PM EDT - 3 years ago

GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST

Oct 13, 2022, 8:00 AM EDT - 3 years ago

GT Biopharma Registration statement: Registration Filing

Oct 6, 2022, 8:18 AM EDT - 3 years ago

GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Oct 4, 2022, 4:10 PM EDT - 3 years ago

GT Biopharma Announces Adjournment of Special Shareholders Meeting

Oct 4, 2022, 8:00 AM EDT - 3 years ago

GT Biopharma Proxy statement: Proxy Filing

Sep 12, 2022, 9:34 AM EDT - 4 years ago

GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies

Sep 8, 2022, 7:30 AM EDT - 4 years ago

GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September

Aug 30, 2022, 6:00 PM EDT - 4 years ago

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

Aug 17, 2022, 8:00 AM EDT - 4 years ago

GT Biopharma Proxy statement: Proxy Filing

Aug 11, 2022, 9:35 AM EDT - 4 years ago

GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

Aug 11, 2022, 7:00 AM EDT - 4 years ago

GT Biopharma Quarterly report: Q2 2022

Aug 11, 2022, 7:00 AM EDT - 4 years ago

GT Biopharma Earnings release: Q2 2022

Jun 10, 2022, 8:00 AM EDT - 4 years ago

GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

May 16, 2022, 8:01 AM EDT - 4 years ago

GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update

May 16, 2022, 7:00 AM EDT - 4 years ago

GT Biopharma Quarterly report: Q1 2022

May 16, 2022, 7:00 AM EDT - 4 years ago

GT Biopharma Earnings release: Q1 2022

May 12, 2022, 8:00 AM EDT - 4 years ago

GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference

calderinho May. 27 at 9:42 AM

$GTBP

0 · Reply

stocks_2watch May. 26 at 6:17 AM

Interview - GT BioPharma ($GTBP): TriKE®️ Platform, Cancer Trials, and Clinical Milestones, latest: https://www.youtube.com/watch?v=Wktvzn0MzQ4

0 · Reply

BigD_Love May. 22 at 3:46 PM

$GTBP Really nice move here today… LFG! 👊🏻

1 · Reply

DARKP00L May. 22 at 12:18 PM

$GTBP 08:11 on May. 22 2026 Nasdaq Grants GT Biopharma Additional 180 Days To Regain Compliance #tradeideas

0 · Reply

focafoca99 May. 22 at 12:17 PM

$GTBP notified Nasdaq that it received an additional 180‑day compliance period to regain $1.00 minimum bid price.

0 · Reply

1flaguy May. 22 at 12:10 PM

$GTBP They got the approval for another 180 days for NASDAQ

0 · Reply

Waterwing May. 21 at 9:28 PM

$GTBP

0 · Reply

Noetic83 May. 20 at 1:04 PM

$GTBP in @ .4399

0 · Reply

Outcomes May. 19 at 11:51 PM

$GTBP $IBRX $CRDL ....saw a TV ad for GTBP and decided to take a look 🤔🤣

0 · Reply

The_Capt May. 19 at 3:23 PM

$GTBP All Aboard 🚀🌜

0 · Reply

thrushpuppy May. 19 at 10:45 AM

$GTBP The initial 180‑day compliance period expired today, May 19, 2026. Sources show the Nasdaq notice dated Nov 20, 2025 set that deadline; the company must have regained a $1.00+ closing bid for 10 consecutive business days before today to cure under an alternative shorter standard, or else face delisting proceedings or seek an extension/remediation (e.g., reverse split).

1 · Reply

focafoca99 May. 18 at 7:36 PM

$GTBP dosed its first patient in a Phase 1 trial of GTB-5550, the first subcutaneous B7‑H3 NK‑cell engager.

0 · Reply

CHItraders May. 15 at 12:21 PM

📊 GT Biopharma $GTBP Q1 Earnings ❌ Earnings Miss Adj. EPS: $(0.11) YoY: ↑ 66.67% (from $(0.33))

0 · Reply

TheWinningStock May. 14 at 9:34 PM

$GTBP <<--This is 💩💩💩👎 $IBRX <<--- The real deal 🤑🚀 $CRDL <<--- another winner 🤑

0 · Reply

realditzy May. 14 at 9:26 PM

$GTBP where do we think this is going ?

1 · Reply

topstockalerts May. 14 at 8:00 PM

$GTBP I wasn’t expecting this name to be leading today.

0 · Reply

realditzy May. 14 at 7:56 PM

$GTBP

1 · Reply

SolomonSD May. 14 at 7:51 PM

$GTBP easy short

0 · Reply

Investing4Knowledge May. 14 at 6:33 PM

$GTBP - moonshots and rainbows

0 · Reply

Noetic83 May. 14 at 6:29 PM

$GTBP im at .44

1 · Reply

The_Assassin May. 14 at 6:20 PM

$GTBP solid news First patient dosed in GTB-5550 Phase 1 trial triggers 28% premarket surge. GT Biopharma announced first patient dosed in Phase 1 trial of GTB-5550 TriKE (Benzinga exclusive). GTB-5550 is a B7-H3-targeted NK cell engager for solid tumors expressing B7-H3. Milestone follows Feb 2026 FDA IND clearance and builds on earlier preclinical/Phase 1 data. Company expects updates in H2 2026 as dose escalation cohorts advance. Small-cap biotech reaction typical on clinical progress; premarket volume elevated. Extends momentum from prior pipeline

0 · Reply

The_Assassin May. 14 at 6:18 PM

$GTBP looks interesting

0 · Reply

Market Cap	15.87M
Revenue (ttm)	0.00
Net Income (ttm)	-28.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	486,348
Avg Vol	1,189,024
Day's Range	N/A - N/A
Shares Out	36.06M
Stochastic %K	46%
Beta	0.64
Analysts	Sell
Price Target	$3.00